For instance, meta-analysis conveyed poor monoimmunotherapy responses in EGFR-, ALK-, HER2-, RET-, and ROS1-altered positive NSCLC patients, but improved outcomes with combination immunotherapy [255]. This evidence concerns the gene ALK and non-small cell lung carcinoma.